Articles tagged with Sepsis
Researchers found that disabling TRIM13 enhances survival in a mouse model of polymicrobial sepsis. The study suggests targeting TRIM13 or its associated ER quality control machinery as a potential strategy for reprogramming immune competence.
Researchers propose an integrative framework to explain sepsis-induced granulopoiesis shift. Immature neutrophils exacerbate tissue damage and contribute to immune paralysis. Precision interventions targeting metabolic pathways and biomarker-guided stratification are suggested.
Researchers at Adelaide University have discovered a naturally occurring protein that can protect against sepsis by reducing inflammation. The protein, corticosteroid-binding globulin (CBG), has been shown to reduce relative mortality in an animal model with septic shock by over 70 per cent.
The American College of Chest Physicians (CHEST) has certified its first class of critical care advanced practice providers with the CCAPP designation. This achievement recognizes their dedication to high-quality patient care and their role in supporting multidisciplinary critical care teams. The CCAPP certification is designed to vali...
The study validates the use of SOFA-2 in sepsis care and research, demonstrating its ability to identify clinically meaningful organ dysfunction. The findings suggest that incorporating immune markers may not improve predictive performance, highlighting the biological complexity of sepsis.
The American College of Chest Physicians' CHEST Critical Care journal has been added to the Web of Science Core Collection through the Emerging Sources Citation Index. This indexing marks a significant milestone for the journal, increasing access to high-quality research and supporting its commitment to advancing critical care medicine.
A sweeping new study has identified tuberculosis as the predominant cause of deadly sepsis among people with HIV in Africa. Immediate treatment for TB significantly increased survival rates, especially when treatment was started before diagnosis.
In sepsis, endothelial cells undergo programmed death-apoptosis, pyroptosis, ferroptosis, and excessive autophagy, leading to barrier collapse. Targeted therapeutic strategies include glycocalyx protectors, barrier stabilizers, anticoagulant approaches, which aim to repair or replace the damaged endothelial barrier.
Researchers at Griffith University have successfully conducted a Phase II clinical trial in China, showing promising results for a carbohydrate-based drug candidate called STC3141. The treatment aims to reduce organ damage and reverse biological responses associated with sepsis.
Salk Institute scientists found distinct disease courses and tolerance mechanisms in younger and older mice with sepsis, indicating a need for age-tailored therapies. The study suggests that future treatments may focus on controlling infection-generated damage rather than just targeting the pathogen.
Acute sepsis alters fluid kinetics and creates a 'third space' resistant to adrenergic modulation, leading to maldistribution of crystalloid fluid. Vasoactive drugs have limited effect on fluid distribution in septic sheep compared to healthy animals.
Researchers at the University of Minnesota Medical School identified a key protein called GDF3 that drives inflammatory responses in older adults. The study showed that GDF3 signals through SMAD2/3, inducing permanent changes in the genome and increasing inflammatory cytokines.
A new study from the University of Gothenburg has found that high teenage BMI and poor physical fitness are associated with a higher risk of developing severe bacterial infections in adulthood. The study, which followed over 44,000 men for three decades, shows that even at high normal weight, individuals are already at increased risk.
A precision medicine-based approach tailors treatment to each patient's unique immune status, improving disease severity and reducing organ failure. The study reveals a significant improvement in clinical outcomes for patients with specific types of sepsis.
Precision immunotherapy targeting macrophage activation–like syndrome and sepsis-induced immunoparalysis improved organ dysfunction by day 9 compared to placebo. The study suggests that this approach can be a promising treatment option for sepsis patients.
Researchers have discovered that a mitochondrial mutation can remodel immune cell function and inflammatory signalling, leading to whole-body issues in animal models. This finding offers a plausible hypothesis for why individuals with these disorders often experience problems with multiple organs and repeated infections.
Researchers found that hospital-acquired bacteria Pseudomonas aeruginosa often spread from the lungs to the gut in patients, heightening the risk of life-threatening sepsis. The study also identified frequent DNA changes associated with antimicrobial resistance, making treatment more difficult.
A landmark trial has shown that a structured approach to infection prevention and treatment can save women's lives. The programme reduced severe maternal infections and deaths by about one-third (32%) compared to usual care.
Researchers have discovered a new gene, ALOX15, that protects against sepsis-induced lung injury in mouse models. The findings suggest that mild lung thrombosis may actually reduce the severity of lung damage from sepsis, offering a potential novel therapeutic strategy.
In response to rising RSV cases, ECDC advises policymakers and public health authorities on effective ways to mitigate the impact of RSV disease in infants. Immunisation interventions, including long-acting monoclonal antibodies and maternal vaccines, can prevent severe illness and hospitalization.
A 47-year-old man from New Jersey died after consuming beef due to a tick-borne meat allergy caused by the Lone Star tick's alpha-gal sugar. Researchers identified the allergy and its link to fatal anaphylaxis, urging physicians to investigate severe abdominal pain after eating red meat in areas with high Lone Star tick populations.
Researchers found that early clindamycin administration significantly improved recovery rates in patients with invasive Group A Streptococcus (iGAS) infections. The study also showed that M1uk strain does not worsen prognosis in critically ill adults, but prompt treatment remains crucial.
A deep learning model developed by researchers identified subgroups of ICU patients with sepsis who could benefit from corticosteroid therapy. Patients with severe metabolic acidosis and circulatory dysfunction benefited the most from treatment.
Researchers focus on unraveling immunoregulatory mechanisms in sepsis, exploring the NF-κB and JAK/STAT signaling pathways. Emerging treatments aim to mitigate hyperinflammation and prevent organ failure through personalized, multi-target modulatory approaches.
Two landmark international studies published in The Lancet and Nature Medicine expose the need for faster recognition, better diagnostics, and personalized treatment pathways to combat pneumonia and sepsis. Irish ICUs face a shortage of beds, with implications for delayed care and increased mortality.
The editorial highlights how biological sex and gender inequities contribute to suboptimal sepsis treatment, potentially compromising outcomes for women. Hormonal fluctuations, body composition, and renal clearance all influence drug processing, yet these variables are rarely considered in dosing algorithms.
The article argues that a universal 30 mL/kg fluid bolus is no longer appropriate and instead calls for a balanced, individualized approach to fluid management in septic shock. This approach considers the patient's comorbidities, infection source, and estimated fluid losses, and guides management by frequent reassessment.
A study published in the Journal of Intensive Medicine found that moderate-dose corticosteroids improve sepsis patient recovery rates by stabilizing immune cells and reducing inflammation. The treatment also shows protective effects on the heart and vascular system, preventing cardiovascular failure and organ damage.
Researchers developed AI models to identify high-risk children for sepsis within 48 hours, enabling early preemptive care. The study used electronic health record data from the Emergency Department and showed robust balance in identifying at-risk children without overidentifying those who are not at risk.
Researchers use microchips with human tissue to study brain damage caused by sepsis and neurodegenerative diseases, finding that the blood-brain barrier breaks down under stress. The technology also reveals how pericytes support the barrier and may lead to new treatments for preserving or introducing these cells.
Researchers developed a collection of blood tests that assess genetic activity patterns in immune cells to reveal patient immune states. These tests could help physicians determine diagnosis and care protocols for patients with suspected infections or critical conditions, providing more accurate diagnoses and treatment guidance.
A study published in The Lancet Regional Health – Western Pacific found that most newborn infections in Southeast Asia are caused by bacteria unlikely to respond to current treatments, highlighting the need for updated diagnostic and treatment guidelines. Locally relevant data is crucial for guiding routine medical decisions, and new a...
The Improving Pediatric Sepsis Outcomes Collaborative has received the prestigious John M. Eisenberg Award, recognizing outstanding leadership and innovation in reducing pediatric sepsis mortality. The award highlights programs demonstrating impact, innovation, sustainability, replicability, and data-driven success.
A large community-based study has found that individuals with type 2 diabetes are at a doubled risk of developing sepsis, particularly among younger adults and men. The study identified several modifiable risk factors, including smoking, high blood sugar, and complications of diabetes.
Scientists have developed a monoclonal antibody to combat life-threatening inflammatory diseases like sepsis and ARDS. The antibody shows promise in blocking the immune system's hyperactive response and restoring healthy function without unwanted side effects.
Researchers discover vitamin B1 restores mitochondrial energy metabolism, drastically reducing lactate production and increasing survival rates in sepsis. The combination of vitamin B1 and glucose proves to be an effective treatment, promising hope for patients affected by this deadly condition.
The article highlights the need for improved sepsis diagnosis, personalized treatment, and innovative trial designs. It advocates for a multifaceted approach integrating timely diagnosis, tailored therapy, and equitable implementation to tackle the global burden of sepsis.
Researchers investigate the role of NUFIP1 in modulating dendritic cell activation during sepsis. They found that NUFIP1 facilitates dendritic cell function by mitigating excessive ER stress, leading to improved immune responses and survival outcomes in septic models.
The American College of Chest Physicians (CHEST) has launched a critical care APP education and certification program, covering 11 topic areas including patient-centered care and pharmacology. The CCAPP Certification Exam is now available, with an August 5 deadline to apply for the 2025 exam.
A new study has identified specific proteins in umbilical cord blood that signal acute systemic inflammation, providing a non-invasive means to diagnose early onset sepsis in preterm newborns. This discovery could lead to the development of a diagnostic test to avoid prolonged antibiotic exposure for infants at risk.
A large cohort study has shown that supplementary treatment with statins can boost survival chances for critically ill patients with sepsis. The results indicate a 39% lower death rate over 28 days after hospital admission.
A new study presents evidence that the Area Deprivation Index (ADI) is not an accurate measure of neighborhood health, particularly in areas with high costs of living. The Healthy Places Index (HPI), on the other hand, was found to be a better predictor of mortality risk for patients hospitalized with sepsis.
Researchers have reexamined the Ashwell-Morell receptor's functions using innovative glycoengineering techniques, clarifying its roles in sepsis and inflammation control. The study reveals that the receptor can bind to a specific type of protein glycan chain, which was previously thought to be incompatible with binding.
Researchers develop a novel self-assembling prodrug, LDO, that targets glycolysis and STING signaling to alleviate inflammation and improve survival in sepsis animal models. LDO reprograms macrophage polarization, reducing cytokine storms and acute lung injury.
Researchers from Radboud University Medical Center found that an existing drug can revive immune cells paralyzed by sepsis, a leading cause of death in ICUs. The study provides new perspectives for the treatment of sepsis and may lead to potential treatments for patients with immune paralysis.
The American College of Chest Physicians' CHEST Critical Care and CHEST Pulmonary journals have been indexed in Elsevier's Scopus database. This achievement is a testament to the high-quality research published in these journals, which provide open access content in pulmonary and critical care medicine.
Preet Chaudhary and Michael Selsted, USC innovators, recognized by the National Academy of Inventors for their work on harnessing the power of the immune system. Their research aims to develop new treatments for diseases such as cancer, rheumatoid arthritis, and sepsis.
Researchers developed an AI-driven model to predict mortality risk in sepsis patients, outperforming traditional scoring systems. The model provides real-time risk alerts and enhances personalized interventions, leading to improved patient outcomes.
Researchers found that patients who received non-compliant care had more complex medical conditions and were more likely to present with unusual symptoms. The study's findings challenge the assumption that SEP-1 compliant care is associated with better survival, highlighting the need for risk-adjusted outcome measures.
This study investigated the effects of Shenfu Decoction on neutrophil chemotactic function in septic mice. The results showed that Shenfu Decoction improved neutrophil chemotaxis function, decreased P2X1 receptor expression, and increased CXCR1 and CXCR2 receptor expression.
Researchers studied how bacteria like Klebsiella pneumoniae cause systemic infection by tracking its movement in mouse models using a barcoding system. They found that bacteria can spread through two routes: metastatic dissemination and direct dissemination, with the former correlating to a stronger infection.
Thousands of Medicare beneficiaries developed postoperative infections up to six months after coronary artery bypass grafting or aortic valve replacement. Women had a 60% greater odds of developing infections, including urinary tract, pneumonia, and sepsis.
A systematic review found no moderate-to-high level evidence that compliance with the Centers for Medicare & Medicaid Services' (CMS) Severe Sepsis and Septic Shock Management Bundle was associated with improved sepsis mortality. The study suggests reconsidering the inclusion of the bundle in the Hospital Value-Based Purchasing program.
Researchers at Salk Institute discover SSRIs like Prozac regulate immune response, preventing sepsis in mice. The findings suggest a potential new use for the popular drug, which could lead to life-saving treatments and enhanced global preparedness for pandemics.
The new center aims to advance understanding, prevention, and management of sepsis through innovative research. Dr. Chanu Rhee and Dr. Michael Klompas will lead the effort, building on their expertise in sepsis surveillance, prevention, treatment, and policy.
Researchers propose systems immunology to tackle sepsis, identifying early warning signs and potential subtypes, which can lead to improved diagnostics and treatment. Targeted funding is urgently needed to develop large-scale omics studies and translate these insights into clinical results.
Researchers discovered that cells caught up in sepsis send out messages to other cells, causing them to die and fueling the spiraling inflammation. By understanding this process, scientists may be able to develop a treatment for inflammatory diseases like sepsis.
A recent study found a significant increase in long-term nursing home stay or death among older adults hospitalized with sepsis during the COVID-19 pandemic. The results suggest that all individuals, regardless of race and ethnicity, experienced increased mortality rates compared to before the pandemic.
A new study from the Salk Institute has discovered that a protein called BCL6 plays a crucial role in maintaining healthy muscle mass. Increasing BCL6 levels successfully reversed muscle losses in mice, suggesting that pairing GLP-1 medications with a BCL6-boosting drug could help counteract unwanted muscle loss.
This study identifies H3K14 lactylation as a crucial regulator of endothelial activation during sepsis-induced ARDS, driving ferroptosis and vascular injury. Inhibition of lactate production alleviated EC activation and improved survival rates in septic mice.